First patient dosed in new study on long-term adherence to

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Aug 7, 2013 at 2:30 AM

First patient dosed in new study on long-term adherence to treatment of opioid dependence with Zubsolv®

Uppsala, Sweden – August 7, 2013 – Orexo today announces that the first patient has been dosed in a study designed to document the long-term effects of Zubsolv® on the retention and adherence to opioid replacement therapy. Other aspects that will be assessed and documented include opioid cravings, effects on withdrawal symptoms, tolerability and how treatment affects patients’ quality of life. In addition, the study will enable Orexo to analyze the impact of Zubsolv on health economic parameters such as cost of treatment, clinical resource utilization and societal benefits. Participation in this new study will be offered as a follow on-study to the patients who enter the ongoing studies on Zubsolv. These studies are focused on defining early treatment efficacy and treatment-adherence, when replacement therapy is initiated for opioid dependent patients. Approximately 750 patients are anticipated to be included across 100 centers in the US, and the study is expected to complete during 2014. “With this study, which is one of three major clinical Zubsolv trials initiated this year, we are evaluating the long term aspects and potential long term benefits of treatment with Zubsolv. The study will not only establish patients’ benefits during continued treatment with Zubsolv but the study has been designed to document the economic impact on the community by keeping more patients in treatment, which will be important in future discussions with payers in the US”, explained Stuart Gitlow, President of American Society of Addiction Medicine and consultant to Orexo. “Orexo is highly committed to improve the treatment of opioid dependence and with this study we will gain significant more insights into how Zubsolv will be used, the patient experience with the product during long-term use, and the impact that Zubsolv may have on patients quality of life. The outcome of the study will guide us in how we can improve our product and patient oriented services further, to ensure an optimal treatment of opioid dependence by use of Zubsolv,” said Nikolaj Sørensen, president and CEO of Orexo. For further information, please contact: Nikolaj Sørensen, President and CEO of Orexo AB Tel: + 46-703 50 78 88, Email: nikolaj.sorensen@orexo.com Robert A DeLuca, President, Orexo US Inc Tel: + 1 201 953 1349, E-mail: robert.deluca@orexo.com About the Study The study will be conducted with approximately 750 patients at 100 centres in the US. It is an un-controlled, open-label study. The participating patients will be analysed at seven visits during 24 weeks. About Zubsolv® Zubsolv is approved by the U.S. Food and Drug Administration (FDA) for Zubsolv. Zubsolv (buprenorphine/naloxone) sublingual tablet CIII, is indicated for use as maintenance treatment for people suffering from opioid dependence and should be used as part of a complete treatment with counselling and psychosocial support. Zubsolv is a novel sublingual formulation of buprenorphine and naloxone using Orexo’s extensive knowledge in sublingual technologies. Through application of its proprietary technologies Orexo has increased the bioavailability of the active ingredient, accelerated dissolve time, reduced tablet size and improved taste. In a comparative acceptability study 9 out of 10 participants choose Zubsolv over the market leader Suboxone Film for a daily treatment. Zubsolv has the potential to be the first new entrant into a growing USD 1.5 billion market, with more than five million patients suffering from opioid dependence and where a majority of patients are not adequately treated today. Market potential for Zubsolv is at peak estimated at above USD 500 million in sales annually. Orexo’s proprietary technology relating to Zubsolv is protected by patents and patent applications in the US and other markets worldwide. Projected expiry dates for this IP range from 2019 to 2032. About Orexo Orexo is an emerging specialty pharma company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery technology. Orexo’s expertise is within the area of reformulation technologies and especially sublingual formulations. The company has a portfolio of revenue-generating US and EU approved products currently marketed under license and a pipeline of several reformulations of approved compounds for areas of unmet medical need. Orexo also has collaboration projects with several international pharmaceutical companies. Orexo, with its headquarters in Sweden, is listed on NASDAQ-OMX. The largest shareholders are Novo A/S and HealthCap. For information about Orexo AB, please visit www.orexo.com. Orexo is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 08:15 am CET on August 7, 2013.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ARTBOX Brings Korean Lifestyle Magic to LA Pop-Up

ARTBOX: From Seoul to La-La Land Here's what caught my eye. It's 2026, and Korean lifestyle retailer ARTBOX is making a splash in the U.S.—kicking things off with a pop-up in LA. Now, usually, I'd be skeptical about pop-ups, but you've got to admire the audacity and timing here. They've picked Melrose Avenue, a hotspot for all things trendy, to introduce their mix of...

Monster Energy Dominates Skateboard Podium at SLS Paris

Monster Energy's Skateboard Triumph Hold the front page, because Monster Energy just pulled off a clean sweep in Paris. The company's team riders dominated the Men's Skateboard Street competition at the SLS Paris 2026, with the iconic Nyjah Huston snagging the top spot. It's a story filled with triumph, grit, and a dash of raw talent in a vibrant field of international...

Monteverde Probes Four Key M&A Deals for Fairness

Examining the Intricacies of Pending M&A The merger and acquisition landscape can be vicious, especially when the sharks—those pesky class action lawyers—start circling. And let me tell you, Monteverde & Associates PC is diving headfirst into the fray, launching inquiries into a handful of these deals. This isn't your first stroll down Wall Street if you’ve seen one...

Monteverde's Equity Alert: Scrutinizing Recent M&A Deals

Diving Into M&A Deals Under Monteverde's Lens Wall Street’s not just about suits and skyscrapers; it’s about the nitty-gritty of deals and whether those numbers add up in the investor's favor. So, when Monteverde & Associates PC throws its weight into scrutinizing mergers and acquisitions, you better believe it's worth a second look. See, they’re digging into four...

Blokees Unveils 90+ New Wonders at Shanghai Fest

A Grand Stage for New Arrivals Picture this: In the bustling and glittering chaos that was the Wonder Festival Shanghai 2026, held from October 3 to 4, Blokees laid down a major marker. More than 500 products, an artillery of imagination and craftsmanship, were on deck across their key lines—Blokees Model Kits and BLOKEES WHEELS. With 90 brand-new creations making their...

Lawsuit Highlights Inaction in School Bus Tragedy

Seeking Justice Amid Heartbreak Tragedy rarely arrives whispered on the wind—more often, it's the train wreck some saw coming long before it hits. The tragic death of Jenna Menias, a 6-year-old from Frankfort, Illinois, falls squarely in this camp. The family's legal lions, Corboy & Demetrio, have slapped two school districts—District 210 and 157-C—with a wrongful...

Black Culture Icon: Plastic-Covered Couch Takes Stage

A Plastic-Laden Piece of History Makes Art Who'd have thought a plastic-covered couch would turn into a cultural artifact? This iconic staple in Black households has done just that, debuting at Brooklyn's CultureCon in a fresh guise. It's more than just an upcycled furniture piece; it's a living archive that encapsulates Black culture, joy, and resilience. The Heart...

Power Knot MEA Wins THE BIZZ 2026 for Excellence

Setting the Pace in Waste Management If there's one thing that sticks in my craw, it's how businesses handle food waste. Power Knot Middle East (PKME) seems to have cracked the code by not just leading the charge in organic waste management but also bagging THE BIZZ 2026 award. They’re not just playing industry games; PKME's pulling the strings with real leadership and...

Unpacking Monteverde's M&A Investigations Hold your horses, folks! The M&A Class Action Firm is stirring the pot with its latest inquiries into some high-profile mergers. We're looking at Lisata Therapeutics, Flag Ship Acquisition Corporation, Baldwin Insurance Group, and ACV Auctions. So what's got Juan Monteverde's legal eagles swooping in on these deals? Well, are we...

SiBionics and PharmaSens Unveil Diabetes Tech at EASD

Shaking Up Diabetes Care: New Tech Unveiled Imagine a world where managing diabetes isn't a juggling act with multiple devices. That's precisely the future SiBionics and PharmaSens are pitching at the European Association for the Study of Diabetes (EASD) 2026 in Milan. Now, let me tell you, these guys aren't just playing around with ideas; they're aiming to radically...